Androgen Receptor Inhibition in CRPC

Part 2: Factors for Selecting a Novel Hormonal Therapy for nmCRPC

During a live virtual event, Evan Yu, MD, discussed the choice of novel hormonal agent for a patient with nonmetastatic castration-resistant prostate cancer.

Part 1: Deciding Whether Next-Generation Scans Are Needed for nmCRPC

During a live event, Evan Yu, MD, discussed how to monitor a patient being treated with androgen deprivation therapy and hormonal agents for nonmetastatic castration-resistant prostate cancer using prostate-specific antigen levels and next-generation imaging.

Part 3: Trials Show Efficacy of Enzalutamide and Darolutamide For CRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 PROSPER trial of enzalutamide and the phase 3 ARAMIS trial of darolutamide in patients with castration-resistant prostate cancer.

Part 2: SPARTAN Trial Shows Efficacy of Apalutamide for CRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 SPARTAN trial of apalutamide in patients with castration-resistant prostate cancer.

Part 1: Guidelines and Recommendations for Treating nmCRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.

Part 3: Combining Therapies to Treat a Patient With CRPC

During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.

Part 2: Concerns When Selecting a Novel Hormonal Agent for CRPC

During a live virtual event, Alicia Morgans, MD, MPH, discussed the choice of novel hormonal agents to combine with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer.

Part 1: The Role and Availability of Germline Testing and PSMA Scans in nmCRPC

During a live virtual event, Alicia Morgans, MD, MPH, discusses the appropriate usage of new genetic testing and PSMA scans in nonmetastatic castration-resistant prostate cancer.

Part 4: Discussing the Use of PET Scans and Metastatic Disease in CRPC

Tanya Dorff, MD, asks the participants of a roundtable discussion about their opinion survival data of androgen receptor–targeted therapy and treating patients with PET scan-only metastatic castration-resistant prostate cancer.

Part 3: Deciding on CRPC Therapy Based on Patient Case and Past Experience

Tanya Dorff, MD, asks the participants of a roundtable discussion which novel hormonal therapy they would choose in a patient with nonmetastatic castration-resistant prostate cancer.

Part 2: Later-Line Therapy in nmCRPC Post Androgen Deprivation Therapy

Tanya Dorff, MD, asks the participants of a roundtable discussion what they would recommend as next-line therapy for a patient with nonmetastatic castration-resistant prostate cancer.

Part 1: Discussing When to Test and Image a Patient With nmCRPC

Tanya Dorff, MD, asks the participants of a roundtable discussion if they would order germline testing and molecular imaging in a patient with nonmetastatic castration-resistant prostate cancer.

Srinivas Reviews Data of Hormonal Agents in the nmCRPC Setting

During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.

Part 4: The Deciding Factors When Picking Between nmCRPC Therapies

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, discusses PSA doubling time and participant experience with androgen receptor inhibitors in castration-resistant prostate cancer.

Part 3: Choosing a Novel Hormonal Agent in CRPC

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, reviews the options for a patient with castration-resistant prostate cancer who progressed on front-line therapy.

Part 2: The Role of PSMA PET Scans in CRPC

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, covers prostate-specific membrane antigen and Axumin testing in castration-resistant prostate cancer.

Part 1: Germline Testing and Molecular Imaging in CRPC

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, leads a conversation on germline testing and molecular imaging in castration-resistant prostate cancer.